FOLH1 and prostate cancer: 68Ga-DOTATATE, 68Ga-DOTATOC and 68Ga-DOTANOC, all of which contain peptides targeting the somatostatin receptor type II (SSTR2), have become clinical standards for imaging neuroendocrine tumours,4 while 68Ga-PSMA, containing a Glu-urea-Lys moiety targeting the prostate-specific membrane antigen (PSMA, glutamate carboxypeptidase II) shows great promise for prostate cancer imaging in clinical trials.5,6